Vertex Stock Lifts As Proteostasis Cystic Fibrosis Treatment Lags Investor's Business Daily
A tiny biotech called Proteostasis won't be able to rival Vertex in cystic fibrosis treatment, analysts said Monday. Vertex stock rose in midday action.
Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals Motley Fool
Rare diseases have proven to be gold mines for Vertex Pharmaceuticals (NASDAQ:VRTX) and Regeneron Pharmaceuticals (NASDAQ:REGN). Vertex's market ...
Vertex Resource Group Ltd.'s Diversification Pays Off Entering 2019 With Record Backlog EnerCom Inc.
Canada NewsWire. SHERWOOD PARK, AB, March 25, 2019. REPORTS FOURTH QUARTER AND FISCAL 2018 FINANCIAL RESULTS. Revenue of $46.2 ...
May 3rd Options Now Available For Vertex Pharmaceuticals (VRTX) Nasdaq
Investors in Vertex Pharmaceuticals, Inc. (Symbol: VRTX) saw new options become available today, for the May 3rd expiration. At Stock Options Channel , our ...
Vertex Faces Choice After Second CF Drug Combo Succeeds in Phase 3 Xconomy
An experimental Vertex Pharmaceuticals cystic fibrosis treatment that combines three of the company's drugs has hit the main goals of two late-stage.
CRISPR and Vertex: Front-Runners in Gene-Therapy Moneyshow.com
In addition to high-quality blue chip, long-term holdings, we also occasionally look to long-term.
Is Orkambi deal close? Vertex meets again today with NHS England PMLiVE
A breakthrough in the long-running dispute over Vertex's cystic fibrosis drug Orkambi could be within sight, as the company meets again today with NHS ...
Could Vertex Pharmaceuticals Be a Millionaire-Maker Stock? The Motley Fool
It's dominating the cystic fibrosis market with more promising drugs on the way. Could this biotech stock put you in nine-digit territory?
Why Vertex's Dilemma Makes It the Best Biotech Stock to Buy Now The Motley Fool
Excellent clinical trial results are giving Vertex a problem most biotechs wish they had.
Vertex Aerospace Wins Seat on $12.6B CMMARS Contract PRNewswire
MADISON, Miss., March 21, 2019 /PRNewswire/ -- Vertex Aerospace has been selected as a qualifying offeror and awarded a contract under ...
Still stuck in Orkambi talks, Vertex CEO preps for mano a mano with British health secretary FiercePharma
Vertex and England's health officials have been stuck in pricing negotiations for cystic fibrosis drug Orkambi for years. But now—"finally," as Vertex CEO Jeffrey ...
Vertex CEO, CCO head for U.K. hearing on Orkambi pricing standoff FiercePharma
Years into a standoff between Vertex Pharmaceuticals and NHS England over cystic fibrosis drug prices, the company's top brass is set to participate in a ...
Vertex's Symdeko OK'd in Australia Seeking Alpha
The Australian Therapeutic Goods Administration approves Vertex Pharmaceuticals' (VRTX) SYMDEKO (tezacaftor/ivacaftor and ivacaftor) for the treatment of p.
Vertex CEO promises 'new ideas' to break a UK price stalemate STAT
During a widely anticipated U.K. Parliamentary hearing, Vertex Pharmaceuticals (VRTX) chief executive Jeff Leiden promised to offer “new ideas” for breaking a ...
Re: NHS and Vertex remain deadlocked over price of cystic fibrosis drug The BMJ
Sir. In describing the latest episode in the Vertex saga Jacqui Wise covers the Health and Social Care Committee's assessment of the various arguments (1).